There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Information on this webpage may or may not have been prepared by LSE but is made available without responsibility on the part of LSE. Their forecasts range from $30.00 to $40.00. To screen for more stocks like CARA click … Cara Therapeutics earned a media sentiment score of 1.6 on InfoTrie's scale. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, topping the consensus estimate of ($0.63) by $0.01. View which stocks are hot on social media with MarketBeat's trending stocks report.Identify stocks that meet your criteria using seven unique stock screeners. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.According to analysts' consensus price target of $34.50, Cara Therapeutics has a potential upside of 101.0% from its current price of $17.16.Cara Therapeutics has only been the subject of 3 research reports in the past 90 days.Cara Therapeutics has received 63.50% “outperform” votes from our community.Cara Therapeutics does not currently pay a dividend.Cara Therapeutics does not have a long track record of dividend growth.In the past three months, Cara Therapeutics insiders have sold more of their company's stock than they have bought. Some companies that are related to Cara Therapeutics include Based on aggregate information from My MarketBeat watchlists, some companies that other Cara Therapeutics investors own include Cara Therapeutics trades on the NASDAQ under the ticker symbol "CARA. Cara Therapeutics Inc (CARA) stock is trading at $17.20 as of 1:40 PM on Monday, Aug 3, an increase of $0.76, or 4.61% from the previous closing price of $16.44. All rights reserved. The biopharmaceutical company can be reached via phone at 203-406-3700.Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Learn everything you need to know about successful options trading with this three-part video course.Looking for new stock ideas? Cara Therapeutics had a negative net margin of 480.29% and a negative return on equity of 68.83%. Top institutional investors include SG Americas Securities LLC (0.25%), UBS Group AG (0.07%), Rothschild Investment Corp IL (0.07%) and Zurcher Kantonalbank Zurich Cantonalbank (0.01%). Specifically, they have bought $0.00 in company stock and sold $485,529.00 in company stock.Only 5.70% of the stock of Cara Therapeutics is held by insiders.68.79% of the stock of Cara Therapeutics is held by institutions.
Cara Therapeutics Inc (CARA… One share of CARA stock can currently be purchased for approximately $17.15.Cara Therapeutics has a market capitalization of $802.55 million and generates $19.89 million in revenue each year. Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. "Cara Therapeutics' stock is owned by a variety of retail and institutional investors. Export data to Excel for your own analysis. High institutional ownership can be a signal of strong market trust in this company.Earnings for Cara Therapeutics are expected to grow in the coming year, from ($2.57) to ($2.53) per share.The P/E ratio of Cara Therapeutics is -6.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.The P/E ratio of Cara Therapeutics is -6.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Cara Therapeutics has a P/B Ratio of 3.68. Cara Therapeutics (NASDAQ:CARA) is one of the more promising biotech stocks on the market due to its leading drug candidate, a kidney disease-related pruritus drug known as Korsuva. 4 brokerages have issued 12-month target prices for Cara Therapeutics' stock. The company is also developing Oral KORSUVA (CR845/difelikefalin) that is in Phase II clinical trial for the treatment of pruritus in stage III-V CKD patients; and in Phase I clinical trial for treating pruritus chronic liver disease. For exact dates please refer to bond documentation directly. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable.